A media release issued on Tuesday this week by a usually highly respected medical center in the Los Angeles area is misleadingly entitled, “Hormone therapy can make prostate cancer worse, study finds”. … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk | Tagged: androgen-resistant, androgen-sensitive, epigenetic, glutamate, neuroendocrine, transition | 6 Comments »
Over the next few years we are going to see the development and marketing of a plethora of new tests related to the diagnosis and prognosis of prostate cancer. Some of these tests may have high utility and value. Others are likely to have a much lower value (but still see high use). As an example, let’s look at the (relatively new) Confirm MDx for Prostate Cancer test. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: biopsy, Confirm MDx, epigenetic, gene, methylation, repeat, risk | 2 Comments »
A newly published paper in the Journal of Urology describes a multi-center, prospective study of the potential of the investigational, urine-based, ProCaM™ assay as a test to offer improved evaluation of the need for prostate biopsy among men with an initial total serum PSA level between 2 and 10 ng/ml. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: biopsy, Diagnosis, epigenetic, ProCaM, PSA, risk, test | 7 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 